Vaccine

The composition according to any one of the preceding claims, wherein the RIPR antigen comprises (or consists of):

• (a) an amino acid sequence having at least 80% sequence identity to SEQ ID NO:
• 3;
• (b) EGF domains 7-8 or RIPR (e.g., SEQ ID NO:
• 1);
• and/or
• (c) SEQ ID NO:
• 3.

The composition according to any one of the preceding claims, wherein the RIPR antigen lacks:

• (i) at least 500 amino acids;
• preferably 600 amino acids;
• more preferably 700 contiguous amino acids from SEQ ID NO:
• 1;
• (ii) EGF domains 1-4 of RIPR (e.g., SEQ ID NO:
• 1);
• and/or
• (iii) EGF domains 9-10 of RIPR (e.g., SEQ ID NO:
• 1).

The composition according to any one of the preceding claims, wherein the RIPR antigen comprises (or consists of):

• (a) a sequence having at least 80% sequence identity to SEQ ID NO:
• 5, or SEQ ID NO:
• 6;
• preferably SEQ ID NO:
• 6;
• or
• (b) SEQ ID NO:
• 5 or SEQ ID NO:
• 6;
• preferably SEQ ID NO:
• 6.

The composition according to any one of the preceding claims, wherein the RIPR antigen induces:

• (a) antibodies that have reduced immunodominance compared to antibodies raised against full-length RIPR;
• (b) a higher proportion of inhibitory antibodies compared to full-length RIPR;
• and/or
• (c) antibodies that have increased growth inhibitory activity (GIA) against the blood-stage Plasmodium parasite compared to antibodies raised against full-length RIPR.

The composition according to any one of the preceding claims, wherein the RIPR antigen induces antibodies that have increased growth inhibitory activity (GIA) of at least 50% against the blood-stage Plasmodium parasite;

• wherein optionally:
• (a) the growth inhibitory activity (GIA) of at least 50% is against a plurality of genetic strains of the blood-stage Plasmodium parasite;
• and/or
• (b) the Plasmodium parasite is Plasmodium falciparum.